Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

3.8%

6 terminated/withdrawn out of 160 trials

Success Rate

92.1%

+5.5% vs industry average

Late-Stage Pipeline

24%

38 trials in Phase 3/4

Results Transparency

7%

5 of 70 completed trials have results

Key Signals

35 recruiting5 with results

Enrollment Performance

Analytics

N/A
45(39.5%)
Phase 2
28(24.6%)
Phase 3
19(16.7%)
Phase 4
19(16.7%)
Phase 1
3(2.6%)
114Total
N/A(45)
Phase 2(28)
Phase 3(19)
Phase 4(19)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (160)

Showing 20 of 160 trials
NCT07852637Phase 4Not Yet Recruiting

Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism

Role: collaborator

NCT07817472Not ApplicableNot Yet Recruiting

Optimal Timing of Microaxial Flow Pump(Impella CP) in AMI-related Cardiogenic Shock

Role: lead

NCT07583784Not ApplicableRecruiting

Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMI

Role: lead

NCT07796217Phase 4Recruiting

Comparison of Clopidogrel-based Antiplatelet Agent Treatment and Aspirin Plus Low Dose Rivaroxaban Therapy

Role: collaborator

NCT05493904Not ApplicableActive Not Recruiting

PREcise Percutaneous Coronary Intervention for Stent OptimizatION in Treatment of COMPLEX Lesion (PRECISION-COMPLEX)

Role: lead

NCT06218485Not ApplicableActive Not Recruiting

FFR Versus IVUS With Angiography-Derived FFR for Clinical Outcomes in Patients With Coronary Artery Disease

Role: collaborator

NCT07741721Not ApplicableNot Yet Recruiting

Optimal Timing of Staged Complete Revascularization in STEMI With Multivessel Disease

Role: lead

NCT04284943Not ApplicableRecruiting

Surgical TreAtment for Obesity Related Disease and Onco-Metabolic Surgery

Role: collaborator

NCT06099366Phase 2Recruiting

Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

Role: collaborator

NCT06257394Phase 2Recruiting

Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea

Role: collaborator

NCT05827549Phase 2Recruiting

Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia

Role: collaborator

NCT04968808Not ApplicableRecruiting

Timing of FFR-guided PCI for Non-IRA in NSTEMI and MVD (OPTION-NSTEMI)

Role: lead

NCT06929897Not ApplicableEnrolling By Invitation

PVI Alone vs PVI With Posterior Wall Isolation for Pulse-Field Ablation in Persistent AF

Role: collaborator

NCT04626882Not ApplicableActive Not Recruiting

Timing of FFR-guided PCI for Non-IRA in STEMI and MVD (OPTION-STEMI)

Role: lead

NCT07621458Recruiting

Study on Cutoff Revision Effects and Evaluation of NNT in Primary Aldosteronism

Role: collaborator

NCT06388720Phase 2Recruiting

The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy

Role: collaborator

NCT07497867Recruiting

Long-term Prospective Study of Korean CADASIL Patients

Role: collaborator

NCT05272618Recruiting

Coronary Microvascular Dysfunction Assessments in Myocardial Infarction With Non-Obstructive Coronary Arteries

Role: lead

NCT06954714Not ApplicableRecruiting

Late-lumen Changes After Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stents in De Novo Coronary Lesions

Role: lead

NCT06227754Not ApplicableRecruiting

OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts

Role: lead